Shares of Annovis Bio, Inc. (ANVS) have gained 23.8% over the past four weeks to close the last trading session at $11.10, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $35.40 indicates a potential upside of 218.9%.The average comprises five short-term price targets ranging from a low of $13 to a high of $72, with a standard deviation of $22.13. While the lowest estimate indic ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-39202 Annovis Bio, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorpora ...

Annovis Bio, Inc. (ANVS) closed the last trading session at $11.10, gaining 9% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $34.60 indicates a 211.7% upside potential.The average comprises five short-term price targets ranging from a low of $9 to a high of $72, with a standard deviation of $23.19. While the lowest estimate indicates a decline of 18.9% from the current price leve ...

MALVERN, Pa., March 20, 2024 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE:ANVS), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases, today announced successful completion of data cleaning for its phase II/III study of buntanetap in patients with mild to moderate Alzheimer's disease (AD). Topline efficacy data is expected in April. "We are excited to share that we now move from data cleaning to organization and statistical evaluation of data for our Alzheimer's st ...

$10 Biotech Stock Wall Street Says Will Be Up Over 200% This Year howtogoto / iStock via Getty Images Dementia is a major healthcare problem across the globe. It is estimated by medical professionals that someone develops some form of dementia every three seconds, and about 55-60 million people currently suffer from it, with 78 million predicted by 2030. Alzheimer’s Disease and Parkinson’s Disease are two of the most common manifestations of dementia categorized neurodegenerative disorders. There are a nu ...

As the saying goes, what goes up must come down. This adage holds true for three stocks. With the market seemingly inflated, it’s vital to identify the warning signs of potential crashes before they occur. These stocks hold solid weaknesses and red flags that could signal an imminent burst in their respective bubbles.The first one grapples with declining retail unit sales and deteriorating credit quality. The company wrestles with declining sales and mounting credit risks. The second one faces volatility in ...

MALVERN, Pa., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE:ANVS), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases today announced panel participation in the International Conference on Alzheimer's and Parkinson's Diseases (AD/PD™ 2024), taking place in Lisbon, Portugal March 5-9, 2024.  Maria Maccecchini, PhD, Founder, President, and CEO of Annovis, will join a forum discussion focused on new approaches for alpha-synuclein (αSyn), LRKK2, and GBA ...

MALVERN, Pa., Feb. 14, 2024 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE:ANVS), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases today announced last patient last visit in the phase II/III study of its lead candidate buntanetap in patients with mild to moderate Alzheimer's disease (AD).  "The completion of the Alzheimer's study marks a significant step in our efforts to bring new therapies to patients," said Maria Maccecchini, Ph.D., Founder, President, and CEO ...

February triggered a rollercoaster ride through the stock market’s twists and turns. Amidst the cacophony of growth stocks to sell, three names echo the market with a hint of fundamental caution.Once labeled castles of value potential, these growth stocks stand at a dangerous crossroads. From the bustling aisles of automotive retail to the lofty heights of aerospace and defense and the promising frontiers of biotechnology, each sector carries its tale of uncertainty.Discover the allure of growth stocks comp ...

koto_feja Intro Annovis Bio (NYSE:ANVS) is set to report the results of its Phase 3 trial in early-stage Parkinson’s disease (PD) in the coming weeks. The company’s lead asset, buntanetap (formerly known as posiphen), is a translational inhibitor of alpha synucelein (associated with PD), amyloid precursor protein (Alzheimer’s), TDP-43 (ALS), and other proteins associated with neurodegenerative disease (further discussion of mechanism in our initiation report). While Annovis also has an ongoing Phase 3 t ...